Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors

Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors

SAN DIEGO, March 17, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc.
(Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and
development of adult stem cell modulators to treat orphan diseases, announced
today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.

Dr. Epstein is a strategic consultant to life sciences companies and an
epidemiologist with extensive expertise in pharmacoeconomics and health
outcomes research, having held various positions in academia and public health
before joining the private sector. From 2010 to 2012, Dr. Epstein served as
president of the Medco-UBC Division and as Chief Research and Development
officer of Medco Health Solutions, Inc., a managed healthcare company. In
these roles, Dr. Epstein was responsible for all of Medco's clinical research
initiatives, including the Medco Research Consortium ("Medco") and United
BioSource Corporation. Dr. Epstein served as Medco's Chief Medical Officer
from 1997 to 2010, leading formulary development, clinical guideline
development, drug information services, personalized medicine program
development, and client analytics and reporting. Dr. Epstein is the former
President of the International Society of Pharmacoeconomics and Outcomes
Research (ISPOR), and served on the board of directors of the Drug Information
Association (DIA) and the International Society of Quality of Life, and was
also elected to the AHRQ CERT (Centers for Education and Research on
Therapeutics) Committee. In addition to Fate Therapeutics, Dr. Epstein serves
on the Board of Directors of Illumina, Inc., AVEO Pharmaceuticals, Inc. and
Proteus Digital Health, Inc.

"We are thrilled to welcome Rob to the Fate Therapeutics Board," said
Christian Weyer, M.D., M.A.S., President and CEO of Fate Therapeutics."Rob's
extensive expertise spanning clinical research, reimbursement and health
economics, and his proven leadership in advancing highly innovative,
paradigm-changing technologies to improve patient care will be invaluable to
Fate as we advance our mission of developing novel, transformative stem cell
therapeutics for patients with rare, life-threatening diseases."

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the
discovery and development of pharmacologic modulators of adult stem cells to
treat orphan diseases. The Company utilizes established pharmacologic
modalities, including small molecules and therapeutic proteins, and
well-characterized biological mechanisms to enhance the therapeutic potential
of adult stem cells. The Company has built two adult stem cell modulation
platforms: a hematopoietic stem cell (HSC) modulation platform, which seeks to
optimize the therapeutic potential of HSCs for treating patients with
hematologic malignancies and rare genetic disorders, and a muscle satellite
stem cell modulation platform, which seeks to activate the regenerative
capacity of muscle for treating patients with degenerative muscle disorders.
The Company is presently advancing its lead product candidate, PROHEMA^®, a
pharmacologically-modulated HSC therapeutic, in Phase 2 clinical development
for hematologic malignancies. Fate Therapeutics is also advancing its
proprietary Wnt7a protein analogs in preclinical development for the treatment
of muscular dystrophies. Fate Therapeutics is headquartered in San Diego, CA.
For more information, please visit www.fatetherapeutics.com.

CONTACT: Paul Cox, Stern Investor Relations, Inc.
         212.362.1200, paul@sternir.com

Fate Therapeutics logo
Press spacebar to pause and continue. Press esc to stop.